Check-control of inflammation displayed by bone marrow mesenchymal stem cells in rheumatoid arthritis patients
Loading...
Official URL
Full text at PDC
Publication date
2019
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Taylor & Francis
Citations
Exportar
Citation
Lamas JR, Mucientes A, Lajas C, Fernández-Gutiérrez B, Lópiz Y, Marco F, Jover JA, Abásolo L, Rodriguez-Rodriguez L. Check-control of inflammation displayed by bone marrow mesenchymal stem cells in rheumatoid arthritis patients. Immunotherapy. 2019 Sep;11(13):1107-1116. doi: 10.2217/imt-2019-0091. Epub 2019 Aug 5. PMID: 31378114.
Abstract
Background: Mesenchymal stem cells (MSCs) are a promising treatment of different musculoskeletal diseases including osteoarthritis and rheumatoid arthritis (RA). Results from different approaches in this treatment have been not conclusive. Aim: To analyze factors related to interactions between peripheral blood mononuclear cells (PBMCs) and MSCs and the influence of cellular activation. Materials & methods: PBMCs from RA patients and healthy controls (HC) were obtained. MSCs from bone marrow (BM-MSCs) were obtained from six donors. CD4, CD25, CD69 and CD127 expression was measured by flow cytometry. Repeated measures analysis of variance (ANOVA) models were performed using activation, co-culture with BM-MSCs and time of culture (24 h, 72 h, 6 days) as within-subject variables. Results: PBMCs activated and co-cultured with BM-MSCs showed a lower proportion of CD25-positive and CD25high/CD127low-negative cells in both RA and HC. Additionally, a maintained expression of CD69 was also observed in RA and HC when PBMCs were activated and co-cultured with BM-MSCs. Conclusion: Both PBMC activation grade and RA disease activity influence the immunomodulatory effect of BM-MSCs on T-cell activation.